Survival Benefit Associated With Resection of Locally Advanced Pancreatic Cancer After Upfront FOLFIRINOX Versus FOLFIRINOX Only

Brada, Lilly J H; Daamen, Lois A; Magermans, L.; Walma, Marieke S.; Latifi, Diba; Dam, Ronald M. van; Hingh, Ignace H. J. T. de; Liem, Mike S L; Meijer, Vincent E de; Patijn, Gijs A.; Festen, Sebastiaan; Stommel, Martijn W J; Bosscha, K.; Polée, Marco B.; Nio, Yung; Wessels, Frank J.; Vries, Jan J. J. de; Lienden, Krijn P. van; Bruijnen, R.; Busch, Olivier R.; Koerkamp, Bas Groot; Eijck, Casper van; Molenaar, Q.; Wilmink, H.; Santvoort, Hjalmar C. van; Besselink, Marc G.

doi:10.1097/sla.0000000000005120

Cited by 15 publications

(13 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Adding robust CA 19-9 response to radiographic response assessment of LAPC following ICT seems to improve the diagnostic accuracy for secondary R0 resection, which is strongly associated with long-term survival in LAPC. 1,8,[37][38][39] Despite the prospective and multicenter design of this analysis, our study has some limitations. Although extensive supportive analyses were performed to define the optimal cut-off value, the finding of the optimal cut-off value for CA 19-9 in this study has limitations due to the limited number of tests and further studies are necessary to confirm this cut-off value.…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)

et al. 2022

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)

et al. 2022

View full text Add to dashboard Cite

“…Propensity score matching (PSM), as a very practical, novel, and creative statistical method for evaluating intervention effects using non-randomized controlled data, was conducted to mitigate the baseline differences affecting long-term outcomes between Con-ICC and HBV-ICC, Con-ICC and Stone-ICC, HBV-ICC and Stone-ICC subtypes [ 19 ], which was conducted by SPSS version 25 (IBM Corp., Armonk, NY, USA). Propensity score analysis with 1:1 matching was performed within a range of 0.02 of standard deviation.…”

Section: Methodsmentioning

confidence: 99%

Recurrence and prognosis in intrahepatic cholangiocarcinoma patients with different etiology after radical resection: a multi-institutional study

Chen

et al. 2022

BMC Cancer

View full text Add to dashboard Cite

Objective We aimed to evaluate the prognosis and adjuvant chemotherapy (ACT) in intrahepatic cholangiocarcinoma (ICC) patients with different etiology after radical resection. Methods A total of 448 patients with ICC who underwent radical resection between 2010 and 2018 at ten Chinese tertiary hospitals were analyzed in the study. These patients were divided into conventional ICC (Con-ICC, n = 261, 58.2%), hepatitis B virus ICC (HBV-ICC, n = 102, 22.8%) and hepatolithiasis (Stone-ICC, n = 85,19.0%) subtypes according to different etiology. Propensity score matching (PSM) was conducted to mitigate the baseline differences between Con-ICC and HBV-ICC, Con-ICC and Stone-ICC, HBV-ICC and Stone-ICC subtypes. Results Univariate and multivariate analysis showed that different etiology was a prognostic factor for overall survival and relapse-free survival, and different etiology was an independent risk factor for overall survival in ICC patients, respectively (P < 0.05). In addition, there was a statistical difference for overall survival in early recurrence patients among the three etiological subtypes (P < 0.05). After PSM, the overall survival of patients with Stone-ICC was worse than those of Con-ICC and HBV-ICC subtypes (P < 0.05), while the relapse-free survival of patients with Stone-ICC was equivalent to patients with Con-ICC and HBV-ICC (P > 0.05). In Stone-ICC patients, the median overall survival was 16.0 months and 29.7 months, and the median relapse-free survival was 9.0 months and 20.0 months for non-ACT and ACT patients, respectively (P < 0.05). Conclusion The prognosis of Stone-ICC patients was significantly worse than those of Con-ICC and HBV-ICC patients. Interestingly, postoperative adjuvant chemotherapy can improve the prognosis of Stone-ICC patients effectively.

show abstract

“…Finally, a total of 101,729 participants were qualified for inclusion ( Figure 1 ). Notably, a comparison between included and excluded populations found that standardized differences of most sociodemographic characteristics were less than 0.1 ( 20 ), indicating that the potential for non-participation bias resulting from the exclusion of a huge number of participants was low ( Supplementary Table 2 ).…”

Section: Methodsmentioning

confidence: 99%

Fried food consumption and the risk of pancreatic cancer: A large prospective multicenter study

et al. 2022

View full text Add to dashboard Cite

Background and aimsWhether fried food consumption is associated with the risk of pancreatic cancer remains elusive. We aimed to examine this association in a US population.MethodsA population-based cohort of 101,729 US adults was identified. Fried food consumption was assessed with a validated food frequency questionnaire. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated. Explanatory analyses were conducted to identify main contributor(s) to the observed association.ResultsDuring an average follow-up of 8.86 years (900871.2 person-years), 402 pancreatic cancer cases occurred. High consumption of total fried foods (deep-fried plus pan-fried foods; HRquartile4 vs. 1 0.71, 95% CI 0.51–0.99, Ptrend = 0.047) and deep-fried foods (HRquartile 4 vs. 1 0.64, 95% CI 0.47–0.88, Ptrend = 0.011), but not pan-fried foods (HRquartile 4 vs. 1 0.98, 95% CI 0.73–1.32; Ptrend = 0.815), was found to be associated with a reduced risk of pancreatic cancer in a non-linear dose–response manner, which was not modified by predefined stratification factors and persisted in sensitivity analyses. In explanatory analyses, only chip consumption was found to be inversely associated with the risk of pancreatic cancer; consistently, the initial significant associations between total fried food and deep-fried food consumption and the risk of pancreatic cancer changed to be non-significant after omitting or further adjusting for chip consumption.ConclusionConsumption of deep-fried foods, but not pan-fried foods, is inversely associated with the risk of pancreatic cancer in this US population. The role of deep-fried foods in reducing the risk of pancreatic cancer appears to be mainly attributable to chips. More studies are needed to confirm our findings in other populations and settings.

show abstract

Survival Benefit Associated With Resection of Locally Advanced Pancreatic Cancer After Upfront FOLFIRINOX Versus FOLFIRINOX Only

Abstract: Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Cited by 15 publications

References 44 publications

Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)

Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)

Recurrence and prognosis in intrahepatic cholangiocarcinoma patients with different etiology after radical resection: a multi-institutional study

Fried food consumption and the risk of pancreatic cancer: A large prospective multicenter study

Contact Info

Product

Resources

About